Passive immunotherapies targeting Aβ and tau in Alzheimer's disease

• Published in: Neurobiology of disease Vol. 144; p. 105010
• Main Authors: Plotkin, Steven S., Cashman, Neil R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2020; The Authors. Published by Elsevier Inc; Elsevier
• Subjects: Alzheimer Disease - drug therapy; Alzheimer Vaccines - therapeutic use; Amyloid beta-Peptides - immunology; Antibodies - therapeutic use; Antibodies, Monoclonal, Humanized; Drug Design; Humans; Immunization, Passive; Immunologic Factors - therapeutic use; tau Proteins - immunology
• ISSN: 0969-9961; 1095-953X; 1095-953X
• DOI: 10.1016/j.nbd.2020.105010

Amyloid-β (Aβ) and tau proteins currently represent the two most promising targets to treat Alzheimer's disease. The most extensively developed method to treat the pathologic forms of these proteins is through the administration of exogenous antibodies, or passive immunotherapy. In this review, we discuss the molecular-level strategies that researchers are using to design an effective therapeutic antibody, given the challenges in treating this disease. These challenges include selectively targeting a protein that has misfolded or is pathological rather than the more abundant, healthy protein, designing strategic constructs for immunizing an animal to raise an antibody that has the appropriate conformational selectivity to achieve this end, and clearing the pathological protein species before prion-like cell-to-cell spread of misfolded protein has irreparably damaged neurons, without invoking damaging inflammatory responses in the brain that naturally arise when the innate immune system is clearing foreign agents. The various solutions to these problems in current clinical trials will be discussed. [Display omitted]